nach oben

Drugs

Erschienen in:

01.06.2003 | Adis Drug Profile

Alemtuzumab

verfasst von: James E. Frampton, Antona J. Wagstaff

Erschienen in: Drugs | Ausgabe 12/2003

Einloggen, um Zugang zu erhalten

Abstract

▴ Alemtuzumab is an unconjugated, humanised, monoclonal antibody directed against the cell surface antigen CD52 on lymphocytes and monocytes.
▴ In noncomparative phase I/II studies in patients with B-cell chronic lymphocytic leukaemia (B-CLL) relapsed after or refractory to alkylating agents and fludarabine, intravenous (IV) administration of alemtuzumab 30 mg/day three times weekly for up to 12 weeks was associated with overall objective response (OR) rates of 21–59%. Combining alemtuzumab with fludarabine resulted in ORs >80%.
▴ In noncomparative studies in patients with previously untreated B-CLL, subcutaneous (SC) administration of alemtuzumab alone, or IV in combination with fludarabine, was highly effective, achieving OR rates of around 90%.
▴ IV alemtuzumab was active in patients with chemotherapy-resistant/relapsed T-cell prolymphocytic leukaemia, with reported OR rates of 24–76%.
▴ Alemtuzumab has been incorporated in novel conditioning regimens designed to facilitate stem cell transplantation in haematological malignancies.
▴ Adverse events with alemtuzumab are predictable and manageable. ‘First-dose’ flulike symptoms, frequently seen after IV infusion, can be managed by (pre)medication and minimised by dose escalation (or SC injection). Anti-infective prophylaxis is mandatory. Cytopenias are transient, although red blood cell and platelet support may be required.

Use of tradenames is for product identification purposes only and does not imply endorsement.

Dumont FJ. CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond. Expert Rev Anticancer Ther 2002 Feb; 2(1): 23–35PubMedCrossRef

Andritsos L, Khoury H. Chronic lymphocytic leukemia. Curr Treat Options Oncol 2002 Jun; 3(3): 225–31PubMedCrossRef

Wierda WG, O’Brien S. Immunotherapy of chronic lymphocytic leukemia. Expert Rev Anticancer Ther 2001; 1(1): 73–83PubMedCrossRef

Kalil N, Cheson BD. Management of chronic lymphocytic leukaemia. Drugs Aging 2000 Jan; 16(1): 9–27PubMedCrossRef

Montserrat E. Current and developing chemotherapy for CLL. Med Oncol 2002; 19 Suppl.: S11–9PubMedCrossRef

Robak T, Kasznicki M. Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia. Leukemia 2002; 16(6): 1015–27PubMedCrossRef

Keating MJ. Progress in CLL, chemotherapy, antibodies and transplantation. Biomed Pharmacother 2001; 55(9–10): 524–8PubMedCrossRef

Dillman RO. Monoclonal antibodies in the treatment of malignancy: basic concepts and recent developments. Cancer Invest 2001; 19(8): 833–41PubMedCrossRef

Schriever F, Huhn D. New directions in the diagnosis and treatment of chronic lymphocytic leukaemia. Drugs 2003; 63(10): 953–69PubMedCrossRef

10.

Tallman MS. Monoclonal antibody therapies in leukemias. Semin Hematol 2002 Oct; 39 (4 Suppl. 3): 12–9PubMedCrossRef

11.

Nemecek ER, Matthews DC. Antibody-based therapy of human leukemia. Curr Opin Hematol 2002 Jul; 9(4): 316–21PubMedCrossRef

12.

Byrd JC, Rai KR. What choices are available for treatment of the patient with chronic lymphocytic leukemia who is fludarabine-refractory? Semin Oncol 2000 Aug; 27(4): xii–xv; discussion xv-xviPubMed

13.

Davis AT. Monoclonal antibody-based therapy of lymphoid neoplasms: what’s on the horizon? Semin Hematol 2000 Oct; 37 (4 Suppl. 7): 34–42PubMedCrossRef

14.

Waldmann TA, Levy R, Coller BS. Emerging therapies: spectrum of applications of monoclonal antibody therapy. Hematology (Am Soc Hematol Educ Program) 2000; 394–408

15.

Rai KR. New biologic therapies. Semin Hematol 1999 Oct; 36 (4 Suppl. 5): 12–7PubMed

16.

Maloney DG. Advances in immunotherapy of hematologic malignancies. Curr Opin Hematol 1998 Jul; 5(4): 237–43PubMedCrossRef

17.

Dumont FJ. Alemtuzumab (Millennium/ILEX). Curr Opin Investig Drugs 2001 Jan; 2(1): 139–60PubMed

18.

Hale G, Xia MQ, Tighe HP, et al. The CAMPATH-1 antigen (CDw52). Tissue Antigens 1990; 35: 118–27PubMedCrossRef

19.

Gilleece MH, Dexter TM. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 1993 Aug 1; 82(3): 807–12PubMed

20.

Ginaldi L, De Martinis M, Matutes E, et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 1998 Feb; 22(2): 185–91PubMedCrossRef

21.

Xia M-Q, Hale G, Waldmann H. Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen. Mol Immunol 1993; 30: 1089–96PubMedCrossRef

22.

Hale G, Bright S, Chumbley G, et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood 1983; 62: 873–82PubMed

23.

Hale G, Clark M, Waldmann H. Therapeutic potential of rat monoclonal antibodies: isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes. J Immunol 1985; 134: 3056–61PubMed

24.

Dyer MJS, Hale G, Hayhoe FGJ, et al. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 1989; 73: 1431–9PubMed

25.

Byrd JC, Shinn CA, Jansure J, et al. CAMPATH-1H induces apoptosis in human chronic lymphocytic leukemia cells (CLL) in vitro independent of complement mediated lysis or Fca receptor ligation [abstract no. 556]. Blood 1999 Nov 15; 94 Suppl. 1, Pt 1: 126a

26.

Bannerji R, Kitada S, Flinn IW, et al. Campath-1H antibody induces transmembrane signaling in vitro and in vivo in patients with chronic lymphocytic leukemia (CLL) and promotes tumor clearance in part through caspase mediated apoptosis [abstract no. 3359]. Blood 2001 Nov 16; 98 (Pt 1): 808a

27.

Dyer MJ. The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies. Semin Oncol 1999 Oct; 26 (5 Suppl. 14): 52–7PubMed

28.

Flynn JM, Byrd JC. Campath-1H monoclonal antibody therapy. Curr Opin Oncol 2000 Nov; 12(6): 574–81PubMedCrossRef

29.

Hale G, Phillips JM. Clinical trials with CAMPATH-1 and other monoclonal antibodies. Biochem Soc Trans 1995 Nov; 23(4): 1057–63PubMed

30.

Waldmann H. A personal history of the CAMPATH-1H antibody. Med Oncol 2002; 19 Suppl.: S3–9PubMedCrossRef

31.

Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002 May 15; 99(10): 3554–61PubMedCrossRef

32.

Osterborg A, Werner A, Halapi E, et al. Clonal CD8pos and CD52neg T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52). Eur J Haematol 1997 Jan; 58(1): 5–13PubMedCrossRef

33.

Rawstron AC, Davies FE, Evans PA, et al. CAMPATH1H therapy for patients with refractory chronic lymphocytic leukaemia [abstract no. 97]. Br J Haematol 1998 May; 101 Suppl. 1: 46

34.

Hertenstein B, Wagner B, Bunjes D, et al. Emergence of CD52neg, phosphatidylinositolgycan-anchor-deficient T lymphocytes after in vivo application of Campath-1H for refractory B-cell non-Hodgkin lymphoma. Blood 1995 Aug 15; 86: 1487–92PubMed

35.

Birhiray RE, Shaw G, Guldan S, et al. Phenotypic transformation of CD52pos to CD52neg leukemic T cells as a mechanism for resistance to CAMPATH-1H. Leukemia 2002 May; 16(5): 861–4PubMedCrossRef

36.

Kennedy B, Forsyth PD, Smith GM, et al. CAMPATH-1H therapy does not affect PBSC collection and engraftment in patients with CLL previously treated with fludarabine [abstract no. 786]. Hematol J 2000 Jun; 1 Suppl. 1: 201

37.

Ilex Pharmaceuticals. Campath (Alemtuzumab) package insert. San Antonio (TX): Ilex Pharmaceuticals, 2002 Jan

38.

Isaacs JD, Manna VK, Rapson N, et al. Campath-1H in rheumatoid arthritis: an intravenous dose-ranging study. Br J Rheumatol 1996; 260: 231–40CrossRef

39.

Rebello P, Hale G. Pharmacokinetics of CAMPATH-1H: assay development and validation. J Immunol Methods 2002 Feb 1; 260(1–2): 285–302PubMedCrossRef

40.

Cwynarsky K, Rebello P, Eades A, et al. Serum levels of Campath-1H in recipients of unrelated BMT [abstract no. 828]. Hematol J 2000 Jun; 1 Suppl. 1: 212

41.

Rebello P, Cwynarski K, Varughese M, et al. Pharmacokinetics of CAMPATH-1H in BMT patients. Cytotherapy 2001; 3(4): 261–7PubMedCrossRef

42.

Morris E, Rebello P, Thomson K, et al. Pharmacokinetics of Campath-1H in vivo T cell depletion in non-myeloablative allogeneic transplants: relevance for early adoptive immunotherapy [abstract no. 1998]. Blood 2001 Nov 16; 98 (Pt 1): 478aCrossRef

43.

Keating MJ, O’Brien S, Kontoyiannis D, et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002 Sep; 43(9): 1755–62PubMedCrossRef

44.

Giles FJ, O’ Brien SM, Santini V, et al. Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukaemia: a phase II study. Leuk Lymphoma 1999 Dec; 36(1–2): 57–65PubMedCrossRef

45.

Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002 Aug 1; 100(3): 768–73PubMedCrossRef

46.

Cheson BD, Bennet JM, Rai KR, et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored Working Group. Am J Haematol 1988; 29: 152–63CrossRef

47.

Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996 Jun 15; 87(12): 4990–7PubMed

48.

Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. J Clin Oncol 1997 Apr; 15(4): 1567–74PubMed

49.

Ferrajoli A, O’Brien SM, Williams ML, et al. Campath-1H in refractory hematological malignancies expressing CD-52. A phase II clinical trial of 68 patients [abstract no. 1541]. Blood 2001 Nov 16; 98 (Pt 1): 366a

50.

Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002 Sep 15; 20(18): 3891–7PubMedCrossRef

51.

McCune SL, Gockerman JP, Moore JO, et al. Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Leuk Lymphoma 2002 May; 43(5): 1007–11PubMedCrossRef

52.

Stilgenbauer S, Scherer K, Krober A, et al. Campath-1H in refractory B-CLL —complete remission despite p53 gene mutation [abstract no. 3211]. Blood 2001 Nov 16; 98 (Pt 1): 771aCrossRef

53.

Jensen M, Schulz H, Winkler U, et al. Treatment of relapsed fludarabine resistant B-cell chronic lymphocytic leukemia with Campath-1H (anti-CD52 antibody) [abstract no. 0179]. Ontologie 1999 Aug; 22 Suppl. 1: 53

54.

Rawstron AC, Davies FE, Morgan GJ, et al. Monitoring of residual disease after CAMPATH-1H therapy of refractory chronic lymphocytic leukaemia [abstract no. 429]. Blood 1998 Nov 15; 92 Suppl. 1, Pt 1: 105a

55.

Bowen AL, Zomas A, Emmett E, et al. Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. Br J Haematol 1997 Mar; 96(3): 617–9PubMedCrossRef

56.

Lundin J, Kimby E, Mellstedt H, et al. Hematological recovery after administration of subcutaneous alemtuzumab (Mab-Campath) in previously untreated versus refractory B-CLL [abstract no. 3177]. Blood 2002 Nov 16; 100 (Pt 1): 805aCrossRef

57.

Rai KR, Coutre S, Rizzieri D, et al. Efficacy and safety of alemtuzumab (Campath-1H) in refractory B-CLL patients treated on a compassionate basis [abstract no. 1538]. Blood 2001 Nov 16; 98 (Pt 1): 365a

58.

Rai KR, Keating MJ, Coutre S, et al. Patients with refractory B-CLL and T-PLL treated with alemtuzumab (Campath) on a compassionate basis. A report on efficacy and safety of CAM 511 trial [abstract no. 3165]. Blood 2002 Nov 16; 100 (Pt 1): 802a

59.

Rai K, Hallek M. Future prospects for alemtuzumab (Mab-Campath). Med Oncol 2002; 19 Suppl.: S57–63PubMedCrossRef

60.

Rai KR, Janson D, Driscoll N, et al. Varying modes of maintenance therapy with Campath-1H in chronic lymphocytic leukemia (CLL) [abstract no. 1099]. 38th Annual Meeting of the American Society of Clinical Oncology; 2002 May 18–21; Orlando (FL), Pt 1: 275a

61.

Pangalis GA, Dimopoulou MN, Angelopoulou MK, et al. Campath-1H in B-chronic lymphocytic leukemia: report on a patient treated thrice in a 3 year period. Med Oncol 2000; 17: 70–3PubMedCrossRef

62.

Tison B, Bolin R, Lill J, et al. Benefits of repeated courses of alemtuzumab (Campath) in patients with relapsed/refractory B-CLL [abstract no. 4920]. Blood 2001; 98: 293b–4b

63.

Thieblemont C, Bouafia F, Hornez E, et al. Maintenance therapy with a monthly injection of Campath-1H in refractory chronic leukemia and NHL patients [abstract no. 3178]. Blood 2002 Nov 16; 100 (Pt 1): 805a

64.

Nabhan C, Dyer MJ, Rosen ST. Current status of monoclonal antibody therapy for chronic lymphocytic leukemia. Oncology 2003; 17(2): 253–62PubMed

65.

Faderl S, Thomas DA, O’Brien S, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003; 101(9): 3413–5PubMedCrossRef

66.

Nabhan C, Tallman MS, Riley MB, et al. Phase I study of rituximab and CAMPATH-1H in patients with relapsed or refractory chronic lymphocytic leukemia [abstract no. 1536]. Blood 2001 Nov 16; 98 (Pt 1): 365a

67.

Nabhan C, Rosen ST. Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukemia. Semin Oncol 2002 Feb; 29 (1 Suppl. 2): 75–80PubMedCrossRef

68.

Elter T, Borchmann P, Schulz H, et al. Development of a new, four-weekly schedule (FluCam) with concomitant application of Campath-1H and fludarabine in patients with relapsed/ refractory CLL [abstract no. 3169]. Blood 2002 Nov 16; 100 (Pt 1): 803a

69.

Kennedy B, Rawstron A, Carter C, et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 2002 Mar 15; 99(6): 2245–7PubMedCrossRef

70.

Rai KR, Byrd JC, Peterson BL, et al. A phase II trial of fludarabine followed by alemtuzumab (Campath-1H) in previously untreated chronic lymphocytic leukemia (CLL) patients with active disease: Cancer and Leukaemia Group B (CALGB) Study 19901 [abstract no. 772]. Blood 2002 Nov 16; 100 (Pt 1): 205a

71.

Montillo M, Tedeschi A, Cafro AM, et al. Sequential subcutaneous administration of CAMPATH-1H as treatment of minimal residual disease in CLL patients responding to fludarabine (FAMP) [abstract no. 3175]. Blood 2002 Nov 16; 100 (Pt 1): 804aCrossRef

72.

Montillo M, Cafro AM, Tedeschi A, et al. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Haematologica 2002 Jul; 87(7): 695–700PubMed

73.

Osterborg A, Fassas AS, Anagnostopoulos A, et al. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol 1996 Apr; 93(1): 151–3PubMedCrossRef

74.

Cao TM, Coutre SE. T-cell prolymphocytic leukaemia: update and focus on alemtuzumab (Campath-1H). Hematology 2003; 8(1): 1–6PubMedCrossRef

75.

Matutes E. T-cell prolymphocytic leukemia. Cancer Control 1998 Jan; 5(1): 19–24PubMed

76.

Dearden CE, Matutes E, Catovsky D. Alemtuzumab in T-cell malignancies. Med Oncol 2002; 19 Suppl.: S27–32PubMedCrossRef

77.

Dearden CE, Matutes E, Cazin B, et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 2001 Sep 15; 98(6): 1721–6PubMedCrossRef

78.

Keating MJ, Cazin B, Coutre S, et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol 2002 Jan 1; 20(1): 205–13PubMedCrossRef

79.

Lundin J, Hagberg H, Repp R, et al. Phase II study of alemtuzumab (anti-CD52 monoclonal antibody, Campath-1H) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 2003 Jan 23

80.

Lundin J, Osterborg A, Brittinger G, et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin’s lymphomas: a phase II multicenter study. J Clin Oncol 1998; 16(10): 3257–63PubMed

81.

Hale G, Jacobs P, Wood L, et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant 2000; 26: 69–76PubMedCrossRef

82.

Hale G. Alemtuzumab in stem cell transplantation. Med Oncol 2002; 19 Suppl.: S33–47PubMedCrossRef

83.

Hale G, Slavin S, Goldman JM, et al. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning? Bone Marrow Transplant 2002 Dec; 30(12): 797–804PubMedCrossRef

84.

Hale G, Cobbold S, Novitzky N, et al. CAMPATH-1 antibodies in stem-cell transplantation. Cytotherapy 2001; 3(3): 145–64PubMedCrossRef

85.

Chakrabarti S, Fegan C, Milligan D. Campath 1-H in the bag for T cell depletion in allogeneic peripheral blood progenitor cell transplantation from matched family and unrelated donors reduces both acute and chronic GvHD and limits transplant-related mortality [abstract no. 0277]. Bone Marrow Transplant 2002 Mar; 29 Suppl. 2: S46

86.

Rizzieri DA, Long GD, Vredenburgh JJ, et al. Chimerism mediated immunotherapy using Campath T cell depleted peripheral blood progenitor cells with nonablative therapy provides reliable, durable allogeneic engraftment [abstract no. 2241]. Blood 2000 Nov 16; 96 (Pt 1): 521a

87.

Jacobs P, Wood L, Hale G, et al. Further experience with campath 1H in monoclonal antibody for T-cell depletion of peripheral mononuclear cells in-the-bag [abstract no. 751]. Hematol J 2000 Jun; 1 Suppl. 1: 192

88.

Bunjes D. T cell depletion of allogeneic stem cell grafts with anti-CD 52 monoclonal antibodies: the Ulm experience from 1983–1999. Transfus Sci 2000 Oct; 23(2): 151–62PubMedCrossRef

89.

Kottaridis PD, Milligan DW, Chopra R, et al. In vivo CAMPATH-1H prevents graft-versus host disease following nonmyeloablative stem cell transplantation. Blood 2000; 96(7): 2419–25PubMed

90.

Byrne J, Donovan L, Davy B, et al. Pre-transplant serotherapy with Campath 1H or ATG is effective in preventing GvHD in patients undergoing allogeneic PBSC transplantation from matched unrelated donors [abstract no. P657]. Bone Marrow Transplant 2002 Mar; 29 Suppl. 2: S173–4CrossRef

91.

Buggins AG, Mufti GJ, Salisbury J, et al. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood 2002 Sep 1; 100(5): 1715–20PubMed

92.

Klangsinsirikul P, Carter GI, Byrne JL, et al. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. Blood 2002 Apr 1; 99(7): 2586–91PubMedCrossRef

93.

Ho AYL, Kenyon M, El-Hemaldi I, et al. Reduced-intensity allogeneic hematopoietic stem cell transplantion with alemtuzumab conditioning regimens: survival does not plateau until after day 200. Blood 2003; 101(2): 779–80PubMedCrossRef

94.

O’Brien SM, Thomas DA, Cortes J, et al. Campath-1H for minimal residual disease in CLL [abstract no. 1132]. 37th Annual Meeting of the American Society of Clinical Oncology 2001; 20: 284a

95.

Dyer MJS, Kelsey SM, Mackay HJ, et al. In vivo ‘purging’ of residual disease in CLL with Campath-1H. Br J Haematol 1997 Jun; 97(3): 669–72PubMedCrossRef

96.

Kennedy B, Rawstron AC, Evans P, et al. CAMPATH-1H therapy in 29 patients with refractory CLL: ‘true’ complete remission is an attainable goal [abstract no. 2683]. Blood 1999 Nov 15; 94 Suppl. l,Pt 1: 603

97.

Smith JA. Alemtuzumab: a new option for refractory chronic lymphocytic leukemia? Cancer Pract 2001 Jul-2001 31; 9(4): 211–3PubMedCrossRef

98.

Kennedy B, Hillmen P. Immunological effects and safe administration of alemtuzumab (MabCampath) in advanced B-CLL. Med Oncol 2002; 19 Suppl.: S49–55PubMedCrossRef

99.

Pangalis GA, Dimopoulou MN, Angelopoulou MK, et al. Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders. Med Oncol 2001; 18(2): 99–107PubMedCrossRef

100.

Perkins JG, Flynn JM, Howard RS, et al. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphoma: implications for clinical trials in these patient populations. Cancer 2002; 94(7): 2033–9PubMedCrossRef

101.

Nguyen DD, Cao TM, Dugan K, et al. Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Clin Lymphoma 2002 Sep; 3(2): 105–10PubMedCrossRef

102.

Williams TE, Roach J, Rugg T, et al. Frequency of cytomegalovirus pneumonia following alemtuzumab (Campath) treatment in lymphoid malignancies: review of 1538 patients [abstract no. 4923]. Blood 2001 Nov 16; 98 (Pt 2): 294b

Titel: Alemtuzumab
verfasst von: James E. Frampton
Antona J. Wagstaff
Publikationsdatum: 01.06.2003
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 12/2003
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200363120-00003

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Alemtuzumab

Abstract

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2003

Polycystic Ovary Syndrome and Epilepsy

Alemtuzumab

Tacrolimus

Current Management Strategies for Coexisting Diabetes Mellitus and Obesity

Saquinavir

Alemtuzumab